Who Paid My Doc
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease
Research payments
$782,156
Through program year 2025, $782,156 in research payments was reported against M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease, across 165 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $782,156 | 165 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Edriss Estime Clermont, FL Named on 22 payments
- Henry Levine Orlando, FL Named on 19 payments
- Jatinder Pruthi Lancaster, CA Named on 9 payments
- Christian Andrade Coral Gables, FL Named on 8 payments
- Ronald Fogel Chesterfield, MI Named on 7 payments
- Sartaj Arora West Covina, CA Named on 7 payments
- Saurabh Kapur Chicago, IL Named on 5 payments
- Monika Fischer Indianapolis, IN Named on 4 payments
- Neera Grover Apple Valley, CA Named on 4 payments
- Tauseef Ali Oklahoma City, OK Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.